Crohn's DiseaseNCT05363930
The MOTOR-CD Trial
A study testing Novel motorized spiral enteroscopy and Single balloon enteroscopy in people with Crohn's Disease, run by Asian Institute of Gastroenterology, India at 1 site in India.
Trial summary
Both single-balloon enteroscopy (SBE) and novel motorized spiral enteroscopy (NMSE) are effective techniques for small bowel endoscopy in suspected Crohn's disease (CD). Small bowel endoscopy is indicated for confirming diagnosis when CD is suspected based on clinical features along with cross-sectional small bowel… Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Crohn's Disease
- What is being tested?
- Novel motorized spiral enteroscopy and Single balloon enteroscopy
- Type of treatment
- Pill or oral medicine, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 128 participants
- Where
- 1 siteIndia
- Study dates
- 7 May 2022to 30 Sep 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with suspected of known IBD requiring small bowel endoscopy
- Ability to give a signed informed consent.
- Age ≥18 years -65 years -
Who cannot join
- Patient not fit for general anaesthesia
- Pediatric Patients (<18 years)
- Pregnant or lactating mother
- Post operative cases
- Not willing to participate
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Randomized Controlled Trial Comparing Diagnostic Yield for Small Bowel Endoscopy Between Novel Motorized Spiral and Single Balloon Enteroscopy in Suspected Crohn's Disease (the MOTOR-CD Trial)
Both single-balloon enteroscopy (SBE) and novel motorized spiral enteroscopy (NMSE) are effective techniques for small bowel endoscopy in suspected Crohn's disease (CD). Small bowel endoscopy is indicated for confirming diagnosis when CD is suspected based on clinical features along with cross-sectional small bowel imaging (computed tomography enterography/enteroclysis: CTE or magnetic resonance enterography/enteroclysis: MRE) or capsule endoscopy (CE). It not only helps in diagnosing CD, but it also helps in excluding CD, diagnosing alternate conditions and taking a surgical decision if a tight stricture is found. The pilot study done by the investigators in 177 suspected CD patients (37.2% female, 7-75 years) undergoing total 201 device assisted enteroscopy (DAE) showed that NMSE scores over SBE with regards to small bowel evaluation with complete small bowel coverage and shorter procedure time. The investigators aim to validate this findings by comparing technical performance and diagnostic yield between NMSE (Olympus Medical, Tokyo, Japan) and SBE (Olympus Medical Systems Corporation, Tokyo, Japan) for small bowel evaluation. Additionally the investigators plan to compare depth of insertion, total enteroscopy rates, procedure time, adverse event rates between the two modalities.
To date, no study has compared both modalities in suspected Crohn's disease (CD) requiring small bowel evaluation in a randomized manner. Hence the investigators intend to perform a randomized controlled study based on these preliminary finding with appropriate matching and parallel study design in larger numbers.
Read the detailed description
Study design
Study population Consecutive patients with suspected Crohn's disease requiring small bowel endoscopy based on abnormal imaging or capsule endoscopy shall be recruited.
Study settings:
The proposed study would be conducted in a high volume tertiary GI centre (Asian Institute of Gastroenterology) performing nearly more than 500 SBE/NMSE procedures per year with an well established inflammatory bowel disease (IBD) registry with more than 7000 IBD patients under follow up.
The study is approved by the institutional review boards and ethics committee. Written informed consent would be taken from each participants and the study would conform to the 1975 Declaration of Helsinki ethical guidelines.
Data collection A survey administration software (google forms) would be used to collect the participant data [age, sex, comorbidities, clinical features, smoking status, history of intestinal resection, type of DAE, indication of DAE, CT/MRE location and characteristic of lesions, capsule endoscopy findings, depth of insertion, time taken for the procedure, total enteroscopy rates, enteroscopy finding details, cause of failure if any, DAE findings, histopathology details, impact on management, adverse events, hospital stay and any therapeutic procedure performed e.g. endoscopic balloon dilation (EBD) with details]. Follow-up details for newly diagnosed CD cases would be collected via physical visit or telephonic communication.
Technique and instruments Single balloon enteroscopy: All SBE procedures will be performed with single balloon video-enteroscope (Olympus Medical Systems, Tokyo, Japan) under monitored anaesthesia (deep sedation with propofol). Initially antegrade/retrograde enteroscopy would be performed based on anticipated location in CT failing which enteroscopy would be done from opposite route to reach the lesion. If the desired lesion is not reached via antegrade/retrograde route, hemoclips would be applied or tattooing would be done followed by enteroscopy from opposite direction on the same day under the same anaesthesia using the same overtube. Fluoroscopy would be used in select cases with anticipated therapeutic procedure. All the procedures were done after minimum of 8 hours of fasting and bowel preparation was given with 4 litres of polyethylene glycol (PEG) for all. Duration of procedure would be calculated from the time of introduction of the enteroscope to time of removal. The depth of insertion would be measured using the push and pull technique. If the desired lesion is not reached by a single route and was deemed possible to reach by the other route, the area of maximal insertion shall be marked by India ink tattooing or hemoclip application followed by completion of bidirectional enteroscopy on the same or next working day.
Novel motorized spiral enteroscopy: All the NMSE (Olympus Medical Systems Corporation, Tokyo, Japan) procedures would be performed under general anaesthesia with nasotracheal intubation under fluoroscopic guidance. Four litres of PEG was given to all patients with at least 8 hours of fasting prior to NMSE. Initially antegrade enteroscopy would be performed failing which retrograde enteroscopy would be done to reach the lesion. If the desired lesion is not reached via antegrade route, hemoclips would be applied or tattooing would be done followed by retrograde enteroscopy on the same day under the same anesthesia using the same overtube. The time of procedure will be calculated from insertion of NMSE to its withdrawal. The depth of insertion would be measured by sequential withdrawal technique as described earlier.
All the enteroscopy procedures were performed by four small bowel endoscopists all of whom have performed at least 200 deep enteroscopy. At least 8 biopsies were taken from area of interest during DAE and sent for histopathological analysis. In selected cases, additional samples were sent for detection of tubercular bacilli using mycobacterium tuberculosis (MTB)-polymerase chain reaction (PCR) if clinically tuberculosis was considered as differential diagnosis. Histopathological findings were recorded under the following headings for diagnosing CD: chronic inflammation, architectural distortion and presence of granulomas.
Definitions:
Technical success shall be defined as enteroscope introduction beyond duodenojejunal (DJ) flexure or ileocecal valve via antegrade and retrograde route respectively. The diagnostic yield with DAE shall be defined as the percentage of procedures which confirmed/excluded lesions found on prior cross-sectional imaging (CTE/MRE) or found new/alternate diagnosis explaining the clinical condition. Depth of maximal insertion (DMI) will be defined as the point beyond which DAE advancement was not feasible. Major adverse events are perforation, pancreatitis, bleeding requiring transfusion or procedure related hospitalization. Minor adverse events are superficial mucosal injury, self limiting sore throat/nausea/vomiting, minor bleeding (without need for blood transfusion) or pain abdomen (not requiring hospital admission). Total enteroscopy will be defined as examination of small bowel from DJ flexure to ileocecal valve. Total enteroscopy would be achieved by either uni-directional (antegrade or retrograde route) or bi-directional enteroscopy (using both antegrade and retrograde route). The histopathological diagnosis of CD will be confirmed if non-caseating micro-granulomas are found with either of both of the other two histological features (chronic inflammation and architectural distortion) and alternate diagnosis like small bowel tuberculosis is ruled out based on clinical, radiologic and other relevant findings. Presence of both chronic inflammation and architectural distortion, non-caseating granuloma/chronic inflammation/ architectural distortion alone will be considered suggestive of CD in the appropriate clinical settings.
Sample size
Based on the pilot study by the investigators, diagnostic yield for deep enteroscopy with NMSE and SBE (97.8% and 83.2% respectively, the estimated sample size is total 124 (62 in each group) keeping type 1 error as 0.05 and power as 80%.
Randomisation
Randomisation will be done based on web based randomisation services
Timeline: 2 years Recruitment of 124 suspected CD patients requiring small bowel evaluation over maximum 2 years.
Patient privacy An organised database for the purpose of this study will be formed based on google form with anonymised data set (i.e. name, address, and full post code will be removed, together with any other information which, in conjunction with other data held by or disclosed to the recipient, could identify the patient) which would be entered by clinical research assistant.
- Conditions
- Crohn's Disease
- Being tested
- Novel motorized spiral enteroscopy, Single balloon enteroscopy
- Keywords
- Device-assisted enteroscopy, Single balloon enteroscopy, Novel motorized spiral enteroscopy, total enteroscopy
- Medical subject headings
- Crohn Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Novel motorized spiral enteroscopyDevice
Novel motorized spiral enteroscopy (Olympus Medical Systems Corporation, Tokyo, Japan) procedures would be performed under general anaesthesia with nasotracheal intubation under fluoroscopic guidance. Four litres of PEG was given to all patients with at least 8 hours of fasting prior to NMSE. Initially antegrade enteroscopy would be performed failing which retrograde enteroscopy would be done to reach the lesion. If the desired lesion is not reached via antegrade/retrograde route, hemoclips would be applied or tattooing would be done followed by enteroscopy from opposite direction on the same day under the same anesthesia using the same overtube. The time of procedure will be calculated from insertion of NMSE to its withdrawal. The depth of insertion would be measured by sequential withdrawal technique.
Single balloon enteroscopyDevice
Single balloon enteroscopy will be performed with single balloon video-enteroscope (Olympus Medical Systems, Tokyo, Japan) under monitored anaesthesia (deep sedation with propofol). Initially antegrade/retrograde enteroscopy would be performed based on pre-procedure localization failing which enteroscopy would be done from opposite route to reach the lesion. Hemoclips would be applied or tattooing would be done followed by enteroscopy from opposite direction on the same day under the same anaesthesia using the same overtube. Duration of procedure would be calculated from the time of introduction of the enteroscope to time of removal. The depth of insertion would be measured using the push and pull technique.
| Study group | Role | What they receive |
|---|---|---|
| Single balloon enteroscopy | Active comparator | Patients with suspected Crohn's disease requiring small bowel enteroscopy based on clinical features, laboratory investigation and in cross-sectional imaging (computed tomography/magnetic resonance enterography or enteroclysis/ video capsule endoscopy Receives: Device: Single balloon enteroscopy |
| Novel Motorized Spiral Enteroscopy | Active comparator | Patients with suspected Crohn's disease requiring small bowel enteroscopy based on clinical features, laboratory investigation and in cross-sectional imaging (computed tomography/magnetic resonance enterography or enteroclysis/ video capsule endoscopy Receives: Device: Novel motorized spiral enteroscopy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Comparison of technical success with NMSE and SBE per patient [%]
Percentage of participants in which anatomical region of interest is reached
Measured: 2 years
Secondary outcomes (5)
Comparison of diagnostic yield with NMSE and SBE per procedure [%]
Percentage of enteroscopy procedures in which Crohn's disease or other disease is diagnosed or ruled out
Measured: 2 years
Comparison of procedure time with NMSE and SBE[minutes]
Time from enteroscope insertion to withdrawal
Measured: 2 years
Comparison of depth of maximal insertion with NMSE and SBE [centimetres]
Maximum depth reached by NMSE/SBE from duodenojejunal flexure for antegrade and ileocecal valve for retrograde enteroscopy
Measured: 2 years
Comparison of total enteroscopy rates with NMSE and SBE [percentage]
Percentage of cases in which total small bowel examination is performed
Measured: 2 years
Comparison of adverse events with NMSE and SBE [percentage]
Major adverse events are perforation, pancreatitis, bleeding requiring transfusion or procedure related hospitalization. Minor adverse events are superficial mucosal injury, self limiting sore throat/nausea/vomiting, minor bleeding (without need for blood transfusion) or pain abdomen (not requiring hospital admission).
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 May 2022
- Study start7 May 2022
- Primary completion30 Sep 2022
- Study completion30 Sep 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Crohn's DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 128 participants (actual)
Sponsor and investigators
- Lead sponsor
- Asian Institute of Gastroenterology, India
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05363930
- Sponsor's protocol ID
- MCD 1; version:1.0
- Status last verified
- Sep 2023
- First submitted
- 28 Apr 2022
- Last updated
- 14 Sep 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Pal P, Ramchandani M, Banerjee R, Viswakarma P, Singh AP, Reddy M, Rughwani H, Patel R, Sekaran A, Kanaganti S, Darisetty S, Nabi Z, Singh J, Gupta R, Lakhtakia S, Pradeep R, Venkat Rao G, Tandan M, Reddy DN. Technical performance and diagnostic yield of motorised spiral enteroscopy compared with single-balloon enteroscopy in suspected Crohn's disease: a randomised controlled, open-label study (the MOTOR-CD trial). Gut. 2023 Oct;72(10):1866-1874. doi: 10.1136/gutjnl-2023-329885. Epub 2023 May 17.
PubMed 37197904
Study at a glance
From the registry record, last updated by the sponsor on 14 Sep 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized Controlled Trial Comparing Diagnostic Yield for Small Bowel Endoscopy Between Novel Motorized Spiral and Single Balloon Enteroscopy in Suspected Crohn's Disease (the MOTOR-CD Trial)
- ClinicalTrials.gov ID
- NCT05363930
- Acronym / sponsor ID
- MCD 1; version:1.0
- Conditions
- Crohn's Disease
- Keywords
- Device-assisted enteroscopy, Single balloon enteroscopy, Novel motorized spiral enteroscopy, total enteroscopy
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 128 participants (actual)
- Lead sponsor
- Asian Institute of Gastroenterology, IndiaUniversity, hospital or other
- Study start
- 7 May 2022 (actual)
- Primary completion
- 30 Sep 2022 (actual)
- Study completion
- 30 Sep 2022 (actual)
- First posted
- 6 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Both single-balloon enteroscopy (SBE) and novel motorized spiral enteroscopy (NMSE) are effective techniques for small bowel endoscopy in suspected Crohn's disease (CD). Small bowel endoscopy is indicated for confirming diagnosis when CD is suspected based on clinical features along with cross-sectional small bowel imaging (computed tomography enterography/enteroclysis: CTE or magnetic resonance enterography/enteroclysis: MRE) or capsule endoscopy (CE). It not only helps in diagnosing CD, but it also helps in excluding CD, diagnosing alternate conditions and taking a surgical decision if a tight stricture is found. The pilot study done by the investigators in 177 suspected CD patients (37.2% female, 7-75 years) undergoing total 201 device assisted enteroscopy (DAE) showed that NMSE scores over SBE with regards to small bowel evaluation with complete small bowel coverage and shorter procedure time. The investigators aim to validate this findings by comparing technical performance and diagnostic yield between NMSE (Olympus Medical, Tokyo, Japan) and SBE (Olympus Medical Systems Corporation, Tokyo, Japan) for small bowel evaluation. Additionally the investigators plan to compare depth of insertion, total enteroscopy rates, procedure time, adverse event rates between the two modalities.
To date, no study has compared both modalities in suspected Crohn's disease (CD) requiring small bowel evaluation in a randomized manner. Hence the investigators intend to perform a randomized controlled study based on these preliminary finding with appropriate matching and parallel study design in larger numbers.
Detailed description
Study design
Study population Consecutive patients with suspected Crohn's disease requiring small bowel endoscopy based on abnormal imaging or capsule endoscopy shall be recruited.
Study settings:
The proposed study would be conducted in a high volume tertiary GI centre (Asian Institute of Gastroenterology) performing nearly more than 500 SBE/NMSE procedures per year with an well established inflammatory bowel disease (IBD) registry with more than 7000 IBD patients under follow up.
The study is approved by the institutional review boards and ethics committee. Written informed consent would be taken from each participants and the study would conform to the 1975 Declaration of Helsinki ethical guidelines.
Data collection A survey administration software (google forms) would be used to collect the participant data [age, sex, comorbidities, clinical features, smoking status, history of intestinal resection, type of DAE, indication of DAE, CT/MRE location and characteristic of lesions, capsule endoscopy findings, depth of insertion, time taken for the procedure, total enteroscopy rates, enteroscopy finding details, cause of failure if any, DAE findings, histopathology details, impact on management, adverse events, hospital stay and any therapeutic procedure performed e.g. endoscopic balloon dilation (EBD) with details]. Follow-up details for newly diagnosed CD cases would be collected via physical visit or telephonic communication.
Technique and instruments Single balloon enteroscopy: All SBE procedures will be performed with single balloon video-enteroscope (Olympus Medical Systems, Tokyo, Japan) under monitored anaesthesia (deep sedation with propofol). Initially antegrade/retrograde enteroscopy would be performed based on anticipated location in CT failing which enteroscopy would be done from opposite route to reach the lesion. If the desired lesion is not reached via antegrade/retrograde route, hemoclips would be applied or tattooing would be done followed by enteroscopy from opposite direction on the same day under the same anaesthesia using the same overtube. Fluoroscopy would be used in select cases with anticipated therapeutic procedure. All the procedures were done after minimum of 8 hours of fasting and bowel preparation was given with 4 litres of polyethylene glycol (PEG) for all. Duration of procedure would be calculated from the time of introduction of the enteroscope to time of removal. The depth of insertion would be measured using the push and pull technique. If the desired lesion is not reached by a single route and was deemed possible to reach by the other route, the area of maximal insertion shall be marked by India ink tattooing or hemoclip application followed by completion of bidirectional enteroscopy on the same or next working day.
Novel motorized spiral enteroscopy: All the NMSE (Olympus Medical Systems Corporation, Tokyo, Japan) procedures would be performed under general anaesthesia with nasotracheal intubation under fluoroscopic guidance. Four litres of PEG was given to all patients with at least 8 hours of fasting prior to NMSE. Initially antegrade enteroscopy would be performed failing which retrograde enteroscopy would be done to reach the lesion. If the desired lesion is not reached via antegrade route, hemoclips would be applied or tattooing would be done followed by retrograde enteroscopy on the same day under the same anesthesia using the same overtube. The time of procedure will be calculated from insertion of NMSE to its withdrawal. The depth of insertion would be measured by sequential withdrawal technique as described earlier.
All the enteroscopy procedures were performed by four small bowel endoscopists all of whom have performed at least 200 deep enteroscopy. At least 8 biopsies were taken from area of interest during DAE and sent for histopathological analysis. In selected cases, additional samples were sent for detection of tubercular bacilli using mycobacterium tuberculosis (MTB)-polymerase chain reaction (PCR) if clinically tuberculosis was considered as differential diagnosis. Histopathological findings were recorded under the following headings for diagnosing CD: chronic inflammation, architectural distortion and presence of granulomas.
Definitions:
Technical success shall be defined as enteroscope introduction beyond duodenojejunal (DJ) flexure or ileocecal valve via antegrade and retrograde route respectively. The diagnostic yield with DAE shall be defined as the percentage of procedures which confirmed/excluded lesions found on prior cross-sectional imaging (CTE/MRE) or found new/alternate diagnosis explaining the clinical condition. Depth of maximal insertion (DMI) will be defined as the point beyond which DAE advancement was not feasible. Major adverse events are perforation, pancreatitis, bleeding requiring transfusion or procedure related hospitalization. Minor adverse events are superficial mucosal injury, self limiting sore throat/nausea/vomiting, minor bleeding (without need for blood transfusion) or pain abdomen (not requiring hospital admission). Total enteroscopy will be defined as examination of small bowel from DJ flexure to ileocecal valve. Total enteroscopy would be achieved by either uni-directional (antegrade or retrograde route) or bi-directional enteroscopy (using both antegrade and retrograde route). The histopathological diagnosis of CD will be confirmed if non-caseating micro-granulomas are found with either of both of the other two histological features (chronic inflammation and architectural distortion) and alternate diagnosis like small bowel tuberculosis is ruled out based on clinical, radiologic and other relevant findings. Presence of both chronic inflammation and architectural distortion, non-caseating granuloma/chronic inflammation/ architectural distortion alone will be considered suggestive of CD in the appropriate clinical settings.
Sample size
Based on the pilot study by the investigators, diagnostic yield for deep enteroscopy with NMSE and SBE (97.8% and 83.2% respectively, the estimated sample size is total 124 (62 in each group) keeping type 1 error as 0.05 and power as 80%.
Randomisation
Randomisation will be done based on web based randomisation services
Timeline: 2 years Recruitment of 124 suspected CD patients requiring small bowel evaluation over maximum 2 years.
Patient privacy An organised database for the purpose of this study will be formed based on google form with anonymised data set (i.e. name, address, and full post code will be removed, together with any other information which, in conjunction with other data held by or disclosed to the recipient, could identify the patient) which would be entered by clinical research assistant.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Single balloon enteroscopy | Active comparator | Device: Single balloon enteroscopyPatients with suspected Crohn's disease requiring small bowel enteroscopy based on clinical features, laboratory investigation and in cross-sectional imaging (computed tomography/magnetic resonance enterography or enteroclysis/ video capsule endoscopy |
| Novel Motorized Spiral Enteroscopy | Active comparator | Device: Novel motorized spiral enteroscopyPatients with suspected Crohn's disease requiring small bowel enteroscopy based on clinical features, laboratory investigation and in cross-sectional imaging (computed tomography/magnetic resonance enterography or enteroclysis/ video capsule endoscopy |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Patients with suspected of known IBD requiring small bowel endoscopy
- Ability to give a signed informed consent.
- Age ≥18 years -65 years -
Key exclusion criteria (5 listed)
- Patient not fit for general anaesthesia
- Pediatric Patients (<18 years)
- Pregnant or lactating mother
- Post operative cases
- Not willing to participate
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Novel motorized spiral enteroscopyNovel motorized spiral enteroscopy (Olympus Medical Systems Corporation, Tokyo, Japan) procedures would be performed under general anaesthesia with nasotracheal intubation under fluoroscopic guidance. Four litres of PEG was given to all patients with at least 8 hours of fasting prior to NMSE. Initially antegrade enteroscopy would be performed failing which retrograde enteroscopy would be done to reach the lesion. If the desired lesion is not reached via antegrade/retrograde route, hemoclips would be applied or tattooing would be done followed by enteroscopy from opposite direction on the same day under the same anesthesia using the same overtube. The time of procedure will be calculated from insertion of NMSE to its withdrawal. The depth of insertion would be measured by sequential withdrawal technique. | Device | Novel Motorized Spiral Enteroscopy |
| Single balloon enteroscopySingle balloon enteroscopy will be performed with single balloon video-enteroscope (Olympus Medical Systems, Tokyo, Japan) under monitored anaesthesia (deep sedation with propofol). Initially antegrade/retrograde enteroscopy would be performed based on pre-procedure localization failing which enteroscopy would be done from opposite route to reach the lesion. Hemoclips would be applied or tattooing would be done followed by enteroscopy from opposite direction on the same day under the same anaesthesia using the same overtube. Duration of procedure would be calculated from the time of introduction of the enteroscope to time of removal. The depth of insertion would be measured using the push and pull technique. | Device | Single balloon enteroscopy |
Primary outcome
Comparison of technical success with NMSE and SBE per patient [%]
Time frame: 2 years
Percentage of participants in which anatomical region of interest is reached
5 secondary outcomes
Comparison of diagnostic yield with NMSE and SBE per procedure [%]
Time frame: 2 years
Comparison of procedure time with NMSE and SBE[minutes]
Time frame: 2 years
Comparison of depth of maximal insertion with NMSE and SBE [centimetres]
Time frame: 2 years
Comparison of total enteroscopy rates with NMSE and SBE [percentage]
Time frame: 2 years
Comparison of adverse events with NMSE and SBE [percentage]
Time frame: 2 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Sep 2023.
- Derived from this study: PubMed 37197904Pal P, Ramchandani M, Banerjee R, Viswakarma P, Singh AP, Reddy M, Rughwani H, Patel R, Sekaran A, Kanaganti S, Darisetty S, Nabi Z, Singh J, Gupta R, Lakhtakia S, Pradeep R, Venkat Rao G, Tandan M, Reddy DN. Technical performance and diagnostic yield of motorised spiral enteroscopy compared with single-balloon enteroscopy in suspected Crohn's disease: a randomised controlled, open-label study (the MOTOR-CD trial). Gut. 2023 Oct;72(10):1866-1874. doi: 10.1136/gutjnl-2023-329885. Epub 2023 May 17.
Related trials for Crohn's Disease
Active, not recruitingPhase 4
Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients
Crohn Disease
Enrolling by invitationPhase 4
INSIGHT-IBD Pragmatic Study
Ulcerative Colitis (UC), Crohn Disease (CD)
Active, not recruitingPhase 4
Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch
Pouchitis, Pouches, Ileoanal
RecruitingObservational study
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Inflammatory Bowel Disease, Crohn's Disease
RecruitingPhase 2
NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease
Fibrostenotic Crohn's Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Novel motorized spiral enteroscopy and Single balloon enteroscopy in people with Crohn's Disease, run by Asian Institute of Gastroenterology, India at 1 site in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Comparison of technical success with NMSE and SBE per patient [%] (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05363930, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Sep 2023.